Ovarian Cancer

Vaidehi Mujumdar, MD, discusses how awareness initiatives can help address unmet needs in patients with ovarian cancer on World Ovarian Cancer Day.

Emil Lou, MD, PhD, FACP, discusses the predictive and prognostic use of tumor stroma proportion for outcomes and chemoresistance in ovarian cancer.

Vaidehi Mujumdar, MD, discusses updates in ovarian cancer for 2024 World Ovarian Cancer Day.

R. Wendel Naumann, MD, discusses 2 case studies in platinum-resistant ovarian cancer and the optimal treatment approaches for each patient.

A phase 2 trial of stenoparib in advanced recurrent ovarian cancer has been closed early to enable a follow-on trial with FDA regulatory intent.

Núria Agustí Garcia, MD, discusses the mapping of sentinel lymph nodes in early-stage ovarian cancer.

Yang Yang Hartwich, PhD discusses a study delving into the mechanisms underlying chemoresistance in ovarian cancer.

Treatment with EVT801 was well tolerated and led to a stable disease rate of 46% in patients with advanced ovarian cancer.

Gottfried Konecny, MD, discusses the importance of evaluating PROs in patients with platinum-resistant ovarian cancer receiving mirvetuximab soravtansine.

Gottfried E. Konecny, MD, discusses PRO data for mirvetuximab soravtansine derived from the phase 3 MIRASOL trial.

Ying Liu, MD, MPH, and Tiffany Sia, MD, discuss the benefits of mainstreaming genetic testing in patients with ovarian cancer.

Sara Corvigno, MD, PhD, expands on an analysis that uncovered the CHIP variants that occurred at a higher frequency in patients with ovarian cancer post-chemotherapy.

The phase 2 DENALI trial is investigating azenosertib in patients with high-grade serous ovarian cancer.

Thomas J. Herzog, MD, examines the PAOLA-1 trial results, focusing on the primary endpoint of progression-free survival (PFS) and key secondary endpoint of overall survival for olaparib in combination with bevacizumab for the treatment of advanced ovarian cancer. He discusses the 5-year overall survival data in relation to the PFS data and reviews the safety profile of the combination therapy with over 5 years of median follow-up. Dr. Herzog also considers the impact of these data on clinical decision-making and patient counseling from the perspective of a practicing gynecologic oncologist.

Gottfried Konecny, MD, discusses patient-reported outcomes from the phase 3 MIRASOL trial in platinum-resistant ovarian cancer.

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the ATHENA-MONO trial in newly diagnosed patients with advanced ovarian cancer.

Don S. Dizon, MD, FACP, FASCO, discusses future directions for precision medicine approaches in ovarian cancer.

Oliver Dorigo, MD, PhD, discusses the investigation of CRX100 in patients with recurrent, platinum-resistant ovarian cancer.

Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.

Naomi Adjei, MD, MPH, MSEd, discusses an analysis of the cost-effectiveness of opportunistic salpingectomy for the primary prevention of ovarian cancer.

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the phase 3 ATHENA-MONO trial in newly diagnosed patients with advanced ovarian cancer.

Erin K. Crane, MD, MPH, discusses the impact of the phase 3 PRIMA trial on second-line maintenance approaches in ovarian cancer.

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, shares post-progression and updated survival outcomes with frontline rucaparib maintenance in ovarian cancer.

In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.